Burosumab Meeting

Kyowa Hakko Kirin Co., Ltd.
Forward-looking Statement

The documents in this event contain certain forward-looking statements relating to such items as the company’s (including its domestic and overseas subsidiaries) forecasts, targets and plans. These forward-looking statements are based upon information available to the company at the present time and upon reasonable assumptions made by the company in making its forecasts, but the actual results in practice may differ substantially due to uncertain factors.

These uncertain factors include, but are not limited to, potential risks of the business activities in the pharmaceutical industry in Japan and overseas, intellectual property risks, risk of side effects, regulatory risks, product defect risks, risks of changes to the prices for raw materials, risks of changes to market prices, as well as risks of changes to foreign exchange rates and financial markets.

The documents are used only for the purpose of providing the information on pharmaceutical products (including products under development) to investors, but those contents should not be construed as promotion, advertising, or medical recommendation.
Agenda

1. Opening remarks
   Masashi Miyamoto, Ph.D.,
   Director of the Board, Managing Executive Officer,
   Kyowa Hakko Kirin Co., Ltd

2. Details of XLH, clinical updates, and current pre-launch activities in the U.S.
   Emil D. Kakkis, M.D., Ph.D.,
   CEO and President, Ultragenyx Pharmaceutical Inc.

3. Clinical/regulatory updates and current pre-launch activities in EU
   Tom Sudo, Executive Vice President,
   KRN23 Global Product Lead, Kyowa Kirin International PLC

4. Q&A
The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

If you have any inquiries regarding this presentation, please call:

Corporate Communications Dept, Kyowa Hakko Kirin Co Ltd

Tel: +81-3-5205-7206